The numbers tell a clear story. Eli Lilly's Mounjaro is the undisputed king of the prescription pad right now, with first-quarter sales of $8.66 billion. That's more than double what its nearest rival, Merck's Keytruda, pulled in last quarter. For all the talk of competition, the reality in doctor's offices is that Mounjaro is the runaway leader.
Yet, Novo Nordisk's Wegovy holds a different kind of power. It has a massive existing base of patients and a new growth engine that's already making waves: its pill form. The company reported that more than one million people in the U.S. are now on the Wegovy pill. That's a huge user base, and it points to a shift in how weight-loss treatment is being delivered.
So, who actually gets the script? In practice, it often comes down to practicalities, not just which drug is theoretically better. Cost and insurance coverage are huge factors. A pill might be more convenient, but if the copay is steep or the insurance doesn't cover it, the injectable might be the only option. Doctor familiarity also plays a role. Many physicians have years of experience prescribing the original injectables, and that comfort level can influence the initial recommendation. The bottom line is that while Mounjaro is the current sales champion, Wegovy's scale and its new oral form give it a formidable position. The choice in the exam room is rarely a pure science experiment.
The Product Edge: What Patients Actually Care About
When it comes down to the actual medicine, the core difference is in how they work. Mounjaro is a dual-action drug, hitting two hormonal pathways at once: GLP-1 and GIP. Wegovy is a single-action drug, targeting just the GLP-1 pathway. In clinical trials, that dual attack has translated to greater average weight loss. One major study found Mounjaro patients lost 20.2% of their body weight, while Wegovy patients lost 13.7%. For a long time, that gap was the key selling point for Mounjaro.
But the gap is closing fast. Novo Nordisk has been aggressively pushing its Wegovy dose higher, and the latest move is a game-changer. The company secured approval for a new 7.2mg dose in January 2026. At that level, Wegovy's weight loss results are now comparable to Mounjaro. This isn't just a minor tweak; it directly challenges Mounjaro's primary clinical advantage. In practice, this means doctors and patients have two drugs that can now promise similar outcomes.
So if the results are getting closer, what tips the scale? For most Americans, the answer is often the bottom line. After Eli Lilly's price increase last September, Wegovy is now generally the more affordable option across most dose levels. That affordability is a critical real-world factor. A patient might be drawn to Mounjaro's slightly higher trial weight loss, but if the copay is significantly higher or insurance coverage is tighter, Wegovy becomes the more practical choice. The product edge is narrowing, but the price tag could be the deciding factor for millions of patients.
The Financial Engine: Growth Drivers and Pressure Points
The financial picture for these two giants could not be more different. For Novo Nordisk, the outlook is clouded by a perfect storm of headwinds. The stock has plunged nearly 50% this year, a brutal reaction to management's stark warning that sales this year were likely to fall between 5% and 13%. The reasons are clear: a "painful" push for lower U.S. drug prices, the looming expiration of key patents, and fierce competition. This isn't just a temporary setback; it's a fundamental shift in the company's growth trajectory, forcing a strategic pivot to volume over price.
Eli Lilly, by contrast, is riding a powerful wave of expansion. Its growth driver is international, and it's firing on all cylinders. The inclusion of Mounjaro on China's National Reimbursement Drug List has been a game-changer, fueling a surge in overseas sales. In the first quarter, international revenue for Mounjaro was $4.4 billion, up from $1.2 billion a year ago. This isn't just incremental growth; it's a massive new market opening. While Novo grapples with domestic pressures, Lilly is scaling its dominance globally.
Zoom out, and the long-term opportunity is immense. The global obesity drug market is projected to grow at an 18.3% compound annual rate, ballooning from $19.6 billion to $104.9 billion by 2035. The U.S., with its high obesity rate, is a major market, but it represents only a fraction of the potential patient pool. For Lilly, the path is clear: leverage its clinical edge and now its international reach to capture a larger share of this expanding pie. For Novo, the challenge is to navigate the near-term storm and prove that its massive existing user base and new oral formulation can drive volume and sustain relevance in a market where price and patent protection are now the central battlegrounds.
Catalysts and What to Watch
The near-term catalyst for Novo Nordisk is a major price move. The company has announced plans to slash U.S. list prices for Wegovy and Ozempic by up to 50% and 35% respectively as of January next year. This is a direct response to intense pressure to lower drug costs in the U.S. market. For now, it's a strategic retreat, but it sets the stage for a volume battle. The question is whether the lower price will be enough to offset the inevitable pressure on revenue per patient.
The real race to watch, however, is international. Both companies are scaling up, but the growth engine is clearly outside the U.S. Novo Nordisk's international obesity-drug sales grew 44% in the first quarter, far outpacing its domestic 9% growth. Eli Lilly is on a similar path, with Mounjaro's international revenue hitting $4.4 billion for the quarter. This is where the massive untapped global demand is being tapped. The next key development will be the rollout of their new oral formulations abroad. Novo's Wegovy pill is already seeing strong uptake in the U.S., but its international launch is the next test. Eli Lilly's new weight-loss pill, Foundayo, is also poised to enter these markets. The progress there will be a better indicator of long-term potential than any U.S. sales number.
In this environment, the single most important metric to watch is patient volume and retention. As pricing pressures mount and competition intensifies, the focus shifts from just selling more units to keeping patients on the drug. The Johns Hopkins study found a strong link between online search volume and prescription dispenses, suggesting awareness drives adoption. But the real test is whether patients stay on therapy. For Novo, the planned price cuts are an attempt to secure that volume. For Lilly, the international surge shows it can still attract new patients. The winner will be the company that can best manage both the cost of entry and the long-term relationship with the patient.